Puma Biotechnology Inc(PBYI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | 17.66 | EPS (ttm) | 0.52 | Insider Own | 24.05% | Shs Outstand | 51.1M | Perf Week | -3.08% |
| Market Cap | 0.47B | Forward P/E | - | EPS next Y | - | Insider Trans | -1.13% | Shs Float | 39.2M | Perf Month | 2.47% |
| Enterprise Value | 0.38B | PEG | - | EPS next Q | - | Inst Own | 67.42% | Short Float | 10.9% | Perf Quarter | 26.14% |
| Income | 0.03B | P/S | 2.04 | EPS this Y | - | Inst Trans | 1.94% | Short Ratio | 12.67 | Perf Half Y | 55.1% |
| Sales | 0.23B | P/B | 3.36 | EPS next 5Y | - | ROA | 13.78% | Short Interest | 4.27M | Perf YTD | 53.28% |
| Book/sh | 2.71 | P/C | 5.01 | EPS past 3/5Y | - | ROE | 21.97% | 52W High | -6.32% ($9.73) | Perf Year | 102.67% |
| Cash/sh | 1.82 | P/FCF | 11.44 | Sales past 3/5Y | 0.05% 0.29% | ROIC | 18.7% | 52W Low | 112.09% ($4.30) | Perf 3Y | 169.03% |
| Dividend Est. | - | EV/EBITDA | 9.35 | EPS Y/Y TTM | -46.26% | Gross Margin | 74.83% | Volatility(W/M) | 4.78% 4.26% | Perf 5Y | 27.73% |
| Dividend TTM | - | EV/Sales | 1.65 | Sales Y/Y TTM | -2.86% | Oper. Margin | 13.16% | ATR (14) | 0.4 | Perf 10Y | -84.52% |
| Dividend Ex-Date | - | Quick Ratio | 2.64 | EPS Q/Q | 33.3% | Profit Margin | 11.55% | RSI (14) | 52.24 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.91 | Sales Q/Q | 7.75% | SMA20 | -1.12% ($9.22) | Beta | 1.22 | Target Price | $6 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/6 | SMA50 | 5.91% ($8.61) | Rel Volume | 0.9 | Prev Close | $9.17 |
| Employees | 179 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 300% 6.6% | SMA200 | 27.57% ($7.15) | Avg Volume(3M) | 0.34M | Price | $9.12 |
| IPO | 2012/4/20 | Option/Short | Yes/Yes | Trades | 3147 | Volume | 303,914 | Change | -0.55% |
Company
PBYI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Puma Biotechnology (PBYI) is a US-based, commercial-stage biopharmaceutical company focused on the development and commercialization of oncology therapeutics. Its key product, NERLYNX (neratinib), is approved by the US Food and Drug Administration (FDA) for the treatment of HER2-positive breast cancer and is being actively marketed, while the company is also advancing its follow-on pipeline, including alisertib and other candidates.
Over the past 1 year, on the higher side
6% below its 1-year high.
PBYI makes money exceptionally well
13.16% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at 17.7 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Would have changed by +169.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 67.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FFLS 0.01%
BTR 0.01%
ICPY 0.01%
ROSC 0.01%
RCGE 0.01%It ranks #4 in the industry
Based on market cap of $471M.
PBYI $471M PER 17.7
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is PBYI?
PBYI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PBYI?
The market cap of PBYI is approximately $471M, ranking 3,276 within its sector.
What is the P/E ratio of PBYI?
PBYI has a P/E ratio of approximately 17.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PBYI?
PBYI has recorded a 52-week high of $9.73 and a low of $4.30.
